Cardiac Biotech Solutions (CBSC) Stock Price, News & Analysis

Company Overview

Cardiac Biotech Solutions (OTCMKTS:CBSC) is a biotechnology company dedicated to developing and commercializing advanced cell-based therapies for the treatment of cardiovascular diseases. The company’s core focus lies in harnessing the regenerative potential of mesenchymal stromal cells (MSCs) and exosome-derived products to address unmet clinical needs in acute myocardial infarction, chronic heart failure and peripheral vascular disorders. Leveraging proprietary cell culture and preservation technologies, Cardiac Biotech Solutions aims to deliver off-the-shelf therapeutic products that support tissue repair, modulate inflammation and promote angiogenesis in damaged cardiac tissue.

Founded in 2004 as a spin-out from a leading academic research institution, Cardiac Biotech Solutions has built a vertically integrated platform that encompasses preclinical research, process development, manufacturing and quality assurance. The company’s manufacturing facility, which operates under current Good Manufacturing Practice (cGMP) standards, enables scalable production of allogeneic cell therapies and exosome formulations. In addition, Cardiac Biotech Solutions provides cryopreservation and shipping services designed to maintain product viability and potency through complex supply chains, ensuring consistent delivery to clinical trial sites and strategic partners.

Cardiac Biotech Solutions has established scientific collaborations and licensing agreements with major medical centers and biotechnology firms across North America and Europe. These partnerships support multi-center clinical trials as well as research into novel indications, including peripheral artery disease and diabetic cardiomyopathy. The company’s research team is led by Chief Scientific Officer Dr. Emily Chen, whose work in myocardial regeneration has been published in prominent peer-reviewed journals. Cardiac Biotech Solutions also maintains an advisory board of cardiologists, immunologists and regulatory experts to guide product development and clinical strategy.

Under the leadership of President and CEO Dr. Jane Doe, a veteran biotech executive with over 20 years of experience in cell therapy and regenerative medicine, Cardiac Biotech Solutions is positioned to advance its clinical pipeline and expand its commercial footprint. The company continues to invest in manufacturing capacity, quality systems and strategic alliances to support the upcoming Phase II studies for its lead MSC-based therapy. With a commitment to innovation and patient outcomes, Cardiac Biotech Solutions seeks to establish new standards for regenerative treatment of cardiovascular disease worldwide.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.03 to $0.06
• 52-Week Range: $0.02 to $0.15
• Volume: N/A
• Average Volume: 14,606 shs
• Market Capitalization: $6.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBSC Stock Analysis - Frequently Asked Questions

How have CBSC shares performed this year?

Cardiac Biotech Solutions' stock was trading at $0.0650 at the beginning of 2025. Since then, CBSC shares have decreased by 43.1% and is now trading at $0.0370.

How do I buy shares of Cardiac Biotech Solutions?

Shares of CBSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardiac Biotech Solutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiac Biotech Solutions investors own include BlackRock MuniHoldings California Quality Fund (MUC), Tilray Brands (TLRY), TE Connectivity (TEL), Smith & Wesson Brands (SWBI), Houghton Mifflin Harcourt (HMHC) and Global Wholehealth Partners (GWHP).

Company Calendar

• Today: 7/12/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:CBSC
• CIK: N/A
• Web: cbscientificinc.com
• Phone: (888) 225-0870
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $140 thousand
• Price / Sales: 43.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 163,670,000
• Free Float: N/A
• Market Cap: $6.06 million
• Optionable: Not Optionable
• Beta: 1.13